Literature DB >> 11091753

Low Frequency Loss of Heterozygosity in the BRCA1 Region in Japanese Sporadic Breast Cancer.

.   

Abstract

To investigate the possible involvement of the BRCA1 gene in Japanese sporadic breast cancer we have analyzed loss of heterozygosity (LOH) at the BRCA1 region (17q12-q22) in 101 sporadic breast cancers using 5 microsatellite markers, such as D17S250, D17S846, D17S855, D17S579, and NME1. The frequency of LOH in each markers was 14.9%(11/74), 11.9 %(8/67),14.3%(12/84),5.3%(4/75), and13.3%(9/68),respectively. The incidence of LOH in at least one of 5 markers was 23.8%(24/101). The LOH at the BRCA1 region did not significantly correlate with clinicopathologic factors. Despite using a microdissection method, the LOH frequency in our series was relatively lower than other reports, especially in Western countries. We suggest that the BRCA1 gene might play only a limited role as a tumor suppressor gene in the majority of Japanese sporadic breast cancers.

Entities:  

Year:  1996        PMID: 11091753     DOI: 10.1007/BF02966980

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  33 in total

1.  Accumulation of genetic alterations and progression of primary breast cancer.

Authors:  T Sato; F Akiyama; G Sakamoto; F Kasumi; Y Nakamura
Journal:  Cancer Res       Date:  1991-11-01       Impact factor: 12.701

2.  Tetranucleotide repeat polymorphism at D17S846 maps within 40 kb of GAS at 17q12-q22.

Authors:  W L Flejter; J F Kukowska-Latallo; S Kiousis; S C Chandrasekharappa; S E King; J S Chamberlain
Journal:  Hum Mol Genet       Date:  1993-07       Impact factor: 6.150

3.  Detection of frequent allelic loss on proximal chromosome 17q in sporadic breast carcinoma using microsatellite length polymorphisms.

Authors:  P A Futreal; P Söderkvist; J R Marks; J D Iglehart; C Cochran; J C Barrett; R W Wiseman
Journal:  Cancer Res       Date:  1992-05-01       Impact factor: 12.701

4.  Chromosome anomalies in human breast cancer: evidence for specific involvement of 1q region in lymphocyte cultures.

Authors:  S Pathak; V L Hopwood; G N Hortobagyi; G L Jackson; J I Hughes; D Melillo
Journal:  Anticancer Res       Date:  1991 May-Jun       Impact factor: 2.480

5.  Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium.

Authors:  D F Easton; D T Bishop; D Ford; G P Crockford
Journal:  Am J Hum Genet       Date:  1993-04       Impact factor: 11.025

6.  Genetic alterations of the tumour suppressor gene regions 3p, 11p, 13q, 17p, and 17q in human breast carcinomas.

Authors:  T I Andersen; A Gaustad; L Ottestad; G W Farrants; J M Nesland; K M Tveit; A L Børresen
Journal:  Genes Chromosomes Cancer       Date:  1992-03       Impact factor: 5.006

7.  Loss of heterozygosity at chromosome 17p is associated with HER-2 amplification and lack of nodal involvement in breast cancer.

Authors:  P G Knyazev; E N Imyanitov; O I Chernitsa; I F Nikiforova
Journal:  Int J Cancer       Date:  1993-01-02       Impact factor: 7.396

8.  Somatic mutations in the BRCA1 gene in sporadic ovarian tumours.

Authors:  S D Merajver; T M Pham; R F Caduff; M Chen; E L Poy; K A Cooney; B L Weber; F S Collins; C Johnston; T S Frank
Journal:  Nat Genet       Date:  1995-04       Impact factor: 38.330

9.  Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer.

Authors:  T Sato; A Tanigami; K Yamakawa; F Akiyama; F Kasumi; G Sakamoto; Y Nakamura
Journal:  Cancer Res       Date:  1990-11-15       Impact factor: 12.701

10.  Loss of heterozygosity at selective sites on chromosomes 13 and 17 in human breast carcinoma.

Authors:  S Thorlacius; O Jonasdottir; J E Eyfjord
Journal:  Anticancer Res       Date:  1991 Jul-Aug       Impact factor: 2.480

View more
  1 in total

1.  Loss of heterozygosity at the ATBF1-A locus located in the 16q22 minimal region in breast cancer.

Authors:  Kazuharu Kai; Zhenhuan Zhang; Hiroko Yamashita; Yutaka Yamamoto; Yutaka Miura; Hirotaka Iwase
Journal:  BMC Cancer       Date:  2008-09-16       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.